Standard treatment in advanced ovarian cancer in 2005: the state of the art.
about
Reducing confounding and suppression effects in TCGA data: an integrated analysis of chemotherapy response in ovarian cancer.Tumor-infiltrating T cells correlate with NY-ESO-1-specific autoantibodies in ovarian cancer.Discrete mixture modeling to address genetic heterogeneity in time-to-event regressionRandomized reverse marker strategy design for prospective biomarker validationRecommended patient-reported core set of symptoms and quality-of-life domains to measure in ovarian cancer treatment trials.Xeroderma pigmentosum complementation group C single-nucleotide polymorphisms in the nucleotide excision repair pathway correlate with prolonged progression-free survival in advanced ovarian cancer.Potential target antigens for a universal vaccine in epithelial ovarian cancer.IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors in vivo.A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16(ecto) directed chimeric antigen receptors for recurrent ovarian cancer.Relationship between ERCC1 polymorphisms, disease progression, and survival in the Gynecologic Oncology Group Phase III Trial of intraperitoneal versus intravenous cisplatin and paclitaxel for stage III epithelial ovarian cancerNon-pegylated liposomal doxorubicin for patients with recurrent ovarian cancer: A multicentric phase II trialThe impact of T-cell immunity on ovarian cancer outcomes.Integrated genome-wide DNA copy number and expression analysis identifies distinct mechanisms of primary chemoresistance in ovarian carcinomasTranslational studies of phenotypic probes for the mononuclear phagocyte system and liposomal pharmacology.Expression of tumor antigens on primary ovarian cancer cells compared to established ovarian cancer cell lines.Efficacy and toxicity profile of pegylated liposomal doxorubicin in patients with advanced ovarian cancer.CAR-T cell therapy in ovarian cancer: from the bench to the bedside.Development of anti-human mesothelin-targeted chimeric antigen receptor (CAR) messenger RNA (mRNA)-transfected peripheral blood lymphocytes (CARMA-hMeso) for ovarian cancer therapy.Targeted therapy and immunotherapy for platinum-refractory advanced ovarian adenosquamous carcinoma: a case report.
P2860
Q30576727-1C1B1B80-7DDA-4168-86B5-141DA465F17EQ33377058-19399CEF-5ADD-47DA-AC36-185525405CD1Q33760422-3AA6A16B-1003-43D2-B2B3-99E84783DDEAQ33934952-3DE6C1CC-3487-4B66-B7AD-72CFF6DB3CDBQ33947886-82D0FB75-5827-4DE0-9743-ADF01330B6C2Q33959550-421264B8-52CB-4C76-BE89-F97719732CDAQ34159451-400FFB45-8D37-4571-B8C4-C24A114876EFQ35506724-3B382A17-DD75-4382-B774-0ED46C9772DAQ35627284-E10EB638-E8C0-4C7E-A27B-7C682B061378Q35730375-27DA8240-A96D-44DA-96BA-46447D9FB7E7Q37108705-D7A0F8F2-118C-4D69-9149-1E9655398958Q37118142-5D587950-8788-419F-A222-1C6DAC519108Q37161861-79887BCD-6AB7-4DFD-AA31-9017BBAD6D2AQ37331793-32BFE6D6-C696-41A9-9FC1-C98ADEE47862Q37564665-74798D1C-758F-4E90-AA28-CC6A789E7C35Q40395847-CF7E52E9-1FF6-4400-B265-97950E4FEC08Q42362802-3CC6ABCA-5216-4C37-87AC-CFB2CABA8344Q50025535-D46907F7-6A3F-4ACA-B367-35763B44426CQ55438200-A25DBA51-E107-4288-B43B-180D1AF4EF9A
P2860
Standard treatment in advanced ovarian cancer in 2005: the state of the art.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Standard treatment in advanced ovarian cancer in 2005: the state of the art.
@ast
Standard treatment in advanced ovarian cancer in 2005: the state of the art.
@en
type
label
Standard treatment in advanced ovarian cancer in 2005: the state of the art.
@ast
Standard treatment in advanced ovarian cancer in 2005: the state of the art.
@en
prefLabel
Standard treatment in advanced ovarian cancer in 2005: the state of the art.
@ast
Standard treatment in advanced ovarian cancer in 2005: the state of the art.
@en
P1476
Standard treatment in advanced ovarian cancer in 2005: the state of the art.
@en
P2093
Bookman MA
P304
P356
10.1111/J.1525-1438.2005.00444.X
P478
15 Suppl 3
P577
2005-11-01T00:00:00Z